Sanofi and Novavax probably won't make an appreciable dent in the US, unless for some reason we start to see rare side effects in the mRNA vaccines in the real world that cause their use to be limited or withdrawn.
Sanofi and Novavax probably won't make an appreciable dent in the US, unless for some reason we start to see rare side effects in the mRNA vaccines in the real world that cause their use to be limited or withdrawn.